Development of AhR inhibitors for oral antiviral therapy for COVID-19 patients (Q3988868): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in de: Adding German translations) |
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
||
Property / contained in NUTS | |||
Property / contained in NUTS: Agglomeratie Leiden en Bollenstreek / rank | |||
Normal rank |
Revision as of 20:08, 13 December 2021
Project Q3988868 in Netherlands
Language | Label | Description | Also known as |
---|---|---|---|
English | Development of AhR inhibitors for oral antiviral therapy for COVID-19 patients |
Project Q3988868 in Netherlands |
Statements
399,362.0 Euro
0 references
1,055,117.569 Euro
0 references
37.85 percent
0 references
1 June 2020
0 references
1 June 2021
0 references
Hercules Pharmaceuticals
0 references
2333BD
0 references
9747AT
0 references
Identifiers
OP-2014-2023-Noord-OPSNN0302
0 references